Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Outlook Therapeutics›

Library

Outlook Therapeutics

Outlook Therapeutics: A US-based biopharmaceutical firm focusing on developing complex biosimilar therapeutics.

Cranbury, NJ, US🇺🇸

Founded

Loading

Outlook Therapeutics Website, Blog & Press Pages - aVenture

Outlook Therapeutics - Library

outlooktherapeutics.comCrawled Oct 15, 2026

Topics

Publication type

Search the library

Content origin

Row density

Careers & Hiring

6 pages

Careers/careers
Outlook Therapeutics is bringing LYTENAVA (bevacizumab-vikg) injection, an FDA-approved ophthalmic bevacizumab formulation for neovascular (wet) age-related macular degeneration (nAMD), to retina specialists and their patients.
Director Payer Access/careers/director-payer-access
Director Pricing Contracting Government Reporting/careers/director-pricing-contracting-government-reporting
Director Trade Distribution/careers/director-trade-distribution

Team

2 pages

Board of Directors/about/board-of-directors
Faisal G. Sukhtian has served as chairman since 2025 and as a member of Outlook Therapeutics’ Board of Directors since 2017. Faisal G. Sukhtian is executive director at GMS Holdings and oversees investments in its portfolio.
Senior Leadership/about/senior-leadership

About

2 pages

About/about
Overview/about/overview

Contact

1 page

Contact/contact
Outlook Therapeutics, Inc. 111 S. Wood Ave Unit #100 Iselin, NJ 08830 609.619.3990 Business development and partnering inquiries To inquire regarding partnership opportunities with Outlook Therapeutics, please contact: info@outlooktherapeutics.com Europe:

Homepage

1 page

Homepage/
Outlook Therapeutics is a late clinical-stage biopharmaceutical company developing and launching an ophthalmic formulation of bevacizumab for retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Privacy

1 page

Privacy Policy/privacy-policy